Tirzepatide
SURMOUNT-4
Eli Lilly · Phase 3 · Completed · Enrollment 783
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide (lead-in) | n/r | n/r | n/r | n/r |
| Tirzepatide MTD | 98.49% | n/r | n/r | n/r |
| Placebo | 69% | n/r | n/r | n/r |
Not shown
- Tirzepatide (lead-in): endpoint not reported